Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2018: SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs
Author(s): Mikhail Kosiborod Added: 6 years ago
Mikhail Kosiborod discusses the CVD-REAL 2 study - Lower Risk of Cardiovascular Events and Death Associated With Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs. Filmed on-site at the American College of Cardiology congress 2018 in Orlando, USA. View more

Prevention & Chronic Conditions
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
Author(s): Maki Komiyama , Koji Hasegawa Added: 3 years ago
Thank you very much for your interesting and important comments on our review that discussed smoking cessation to limit the coronavirus disease 2019 (COVID-19) pandemic.1,2 As you pointed out, the reported number of hospitalised COVID-19 patients who are current or former smokers is small.3,4 One reason for this small number of smokers is that an unknown history of smoking may be treated as a non… View more

COVID-19
ESC 2019 - MITRA-FR - Prof Jean-François Obadia
Author(s): Jean-François Obadia Added: 4 years ago
Prof Jean-François Obadia (Civils Hospices of Lyon, FR) discusses 2-year follow-up of the MITRA-FR study: A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation. Filmed on site at ESC 2019 by Radcliffe Cardiology. View more

Heart Failure

Intervention
Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin
Author(s): Rifly Rafiudeen , Peter Barlis , Harvey D White , et al Added: 2 years ago

Vascular Disease and Surgery
P2Y12 Inhibitors for Special Populations in the Asia-Pacific Region
Author(s): Jack Wei Chieh Tan , Derek P Chew , Kin Lam Tsui , et al Added: 2 years ago

Vascular Disease and Surgery

MI/ACS
Pharmacological Treatment of Type 2 Diabetes and CVD
Author(s): Felipe Martínez Added: 3 years ago

Prevention & Chronic Conditions

CV Disease in Special Populations
SGLT-2 Inhibitors and Cardio-renal Outcomes
Author(s): Shelley Zieroth , , Added: 2 years ago
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) andProf Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice. This three-part series, 'SGLT-2 Inhibitors and Cardio-renal… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Wolfgang Koenig Added: 3 years ago
The notion that atherosclerosis carries features of an inflammatory disease has existed for quite some time. As early as 1856, Rudolf Virchow in his Textbook on Pathology mentioned the term “coronaritis”. Almost 150 years later, following the elucidation of major cardiovascular risk factors in the 1950s Framingham Study, Russell Ross entitled his 1999 review on mechanisms of atherosclerosis … View more

Heart Failure

Prevention & Chronic Conditions
Curcumin in Lifestyle Diseases
Author(s): Kana Shimizu , Masafumi Funamoto , Yoichi Sunagawa , et al Added: 3 years ago
Inflammation involves an array of processes in response to tissue damage resulting from oxidative stress or other causes and triggers repair, such as subsequent extracellular matrix remodelling and fibrosis.1–3 Chronic inflammation continues for a prolonged period, lasting from several months to several years, and is characterised by tissue invasion by inflammatory macrophages. This induces the… View more

Prevention & Chronic Conditions
AHA 2018: The Latest Updates on CVOT Data for Type 2 DM Therapies
Author(s): John JV McMurray , Carolyn Lam Added: 5 years ago
Prof Carolyn Lam (National Heart Center, SG) & Prof John McMurray (University of Glasgow, UK) discuss the latest updates on CVOT data for Type 2 DM therapies. Filmed by Radcliffe Cardiology on site at AHA 2018. This peer-to-peer discussion was funded by an unrestricted grant by Novo Nordisk. View more

Prevention & Chronic Conditions